Skip to main content

Adverse event reporting can be found at the bottom of the page.

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

DUPIXENT®

(dupilumab) in uncontrolled Chronic Obstructive Pulmonary Disease

A breakthrough therapy in adults with uncontrolled chronic obstructive pulmonary disease (COPD) for MORE I CAN MOMENTS1 

TARGET

Two key drivers of type 2 inflammation

Discover the science behind DUPIXENT's MoA

REDUCE

Moderate and severe exacerbations

Explore the efficacy results

IMPROVE

How patients breathe and feel

Learn More

Indication

DUPIXENT is indicated in adults as add-on maintenance treatment for uncontrolled COPD characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.1

For additional information, please click here for the Summary of Product Characteristics.

 

ABBREVIATIONS
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long‑acting beta2‑agonist; LAMA, long‑acting muscarinic antagonist; MOA, mechanism of action; MOD, mechanism of disease

REFERENCES

  1. DUPIXENT (dupilumab). Summary of Product Characteristics. 2025. Date last accessed: December 2025. 

MAT-XU-2502771 (v1.0) | December 2025

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com
Back to top
Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement
Back to top

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025